Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, indicating a new version of the site; the available changes point to a backend or UI update rather than a modification of study content.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision was bumped from v3.6.5 to v3.6.6, signaling an updated build of the ClinicalTrials.gov page. This maintenance update does not change the study information displayed.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page revision changed from v3.6.4 to v3.6.5, indicating a site update. The study details remain unchanged.SummaryDifference0.0%

- Check50 days agoChange DetectedUpdated study timeline dates: primary completion now 2026-12-30 and study completion now 2027-06-28. A new Revision: v3.6.4 tag appears, indicating an updated page version.SummaryDifference0.3%

- Check72 days agoChange DetectedThe page revision label updated from v3.6.2 to v3.6.3, indicating a new build of the ClinicalTrials.gov page. This change typically reflects maintenance updates and does not alter the study data or eligibility details.SummaryDifference0.0%

- Check79 days agoChange DetectedThe page's revision line now shows Revision: v3.6.2, replacing the previous v3.6.0. This indicates a newer version of the page has been published.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.